Multivariate Cox regression analysis of prognostic genes and therapeutic mechanisms of gastric cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Identifying new prognostic markers for gastric cancer (GC) is crucial. Four key genes (LMOD1, CRYAB, VCL, MYL9) were found to be independent prognostic factors, indicating poor patient outcomes and potential therapeutic targets.
Area Of Science
- Oncology
- Genetics
- Bioinformatics
Background
- Gastric cancer (GC) presents a high incidence and poor prognosis, necessitating novel prognostic markers.
- Effective diagnosis and treatment strategies for GC require the identification of new predictive indicators.
Purpose Of The Study
- To identify and validate key genes as prognostic markers for gastric cancer.
- To explore the potential of these key genes as therapeutic targets in GC treatment.
Main Methods
- Downloaded gene expression and clinical data from TCGA and GSE84437 datasets.
- Performed independent prognostic analysis, clinical correlation analysis, and constructed a protein-protein interaction (PPI) network.
- Conducted survival analysis, multivariate Cox regression, and functional enrichment analysis.
Main Results
- Screened 74 prognostic related genes (PRG) and identified four key genes (KG): LMOD1, CRYAB, VCL, and MYL9.
- High expression of these key genes correlated with poor prognosis in GC patients.
- Key genes are involved in cell adhesion molecules, adhesion spots, and the PI3K/AKT signaling pathway, validated in the TCGA database.
Conclusions
- The identified key genes (LMOD1, CRYAB, VCL, MYL9) serve as independent prognostic factors for gastric cancer.
- These key genes represent potential therapeutic targets for improving gastric cancer treatment outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...